Skip to main content
SpringerLink
Log in

Antibody-Dependent Enzyme Prodrug Therapy (ADEPT)

  • Protocol
Antibody Engineering

Part of the book series: Springer Protocols Handbooks ((SPH))

The development of antibody-directed enzyme prodrug therapy is reviewed. Antibody-directed enzyme prodrug therapy (ADEPT) generates a cytotoxic drug selectively within deposits of cancer and is designed to give therapy with high levels of tumour selectivity coupled with exceptional potency. This is achieved by giving an enzyme linked to an antibody which targets it to the cancer; prodrug is then given when there are minimal enzyme levels in normal tissues but sufficient in the cancer for prodrug activation. The multi-component nature of ADEPT makes drug development more demanding than it is for developing single agents but is nevertheless being vigorously pursued, and if mastered will have broad application. This review considers how much progress there has been towards practical cancer treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 219.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 279.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 379.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  • Aapro MS, Cameron DA, Pettengell R, Bohlius J, Crawford J, Ellis M, Kearney N, Lyman GH, Tjan-Heijnen VC, Walewski J, Weber DC, Zielinski C (2006) European. Organisation for Research and Treatment of Cancer (EORTC) Granulocyte Colony-Stimulating Factor (G-CSF) Guidelines Working Party EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 42(15):2433–2453

    Article  PubMed  CAS  Google Scholar 

  • Allander SV, Nupponen NN, Ringner M, Hostetter G, Maher GW, Goldberger N, Chen Y, Carpten J, Elkahloun AG, Meltzer PS (2001) Gastrointestinal stromal tumours with kit mutations exhibit a remarkably homogeneous gene expression profile. Cancer Res 61:8624–8628

    PubMed  CAS  Google Scholar 

  • Bagshawe KD (1989) Toward generating cytotoxic agents at cancer sites. Br J Cancer 60:275–281

    Article  PubMed  CAS  Google Scholar 

  • Bagshawe KD, Begent RHJ (1996) First clinical experience with ADEPT. Adv Drug Deliv Rev 22(3):365–367

    Article  CAS  Google Scholar 

  • Bagshawe KD, Sharma SK, Springer CJ, Antoniw P (1995) Antibody directed enzyme prodrug therapy: a pilot scale clinical trial. Tumour Target 1:17–30

    Google Scholar 

  • Begent RHJ, Ledermann JA, Green AJ, Bagshawe KD, Riggs SJ, Searle F, Keep PA, Adam T, Dale RG, Glaser MG (1989) Antibody distribution and dosimetry in patients receiving radiolabelled antibody therapy for colorectal cancer. Br J Cancer 60:406–412

    Article  PubMed  CAS  Google Scholar 

  • Begent RHJ, Verhaar MJ, Chester KA, Casey JL, Green AJ, Napier MP, Hope-Stone LD, Cushen N, Keep PA, Johnson CJ, Hawkins RE, Hilson AJW, Robson L (1996) Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library. Nat Med 2:979–984

    Article  PubMed  CAS  Google Scholar 

  • Bhatia J, Sharma SK, Chester KA, Pedley RB, Boden RW, Read DA, Boxer GM, Michael NP, Begent RHJ (2000) Catalytic activity of an in vivo tumor targeted anti-CEA scFv::carboxypeptidase G2 fusion protein. Int J Cancer 85:571–577

    Article  PubMed  CAS  Google Scholar 

  • Biela BH, Khawli LA, Hu P, Epstein AL (2003) Chimeric TNT-3/human beta-glucuronidase fusion proteins for antibody-directed enzyme prodrug therapy (ADEPT). Cancer Biother Radiopharm 18(3):339–353

    Article  PubMed  CAS  Google Scholar 

  • Blakey DC, Burke PJ, Davies DH, Dowell RI, East SJ, Eckersley KP, Fitton JE, McDaid J, Melton RG, Niculescu-Duvaz IA, Pinder PE, Sharma SK, Wright AF, Springer CJ (1996) ZD2767, an improved system for antibody-directed enzyme prodrug therapy that results in tumor regressions in colorectal tumor xenografts. Cancer Res 56(14):3287–3292

    PubMed  CAS  Google Scholar 

  • Bosslet K, Czech J, Lorenz P, Sedlacek HH, Schuermann M, Seemann G (1992) Molecular and functional characterisation of a fusion protein suited for tumour specific prodrug activation. Br J Cancer 65(2):234–238

    Article  PubMed  CAS  Google Scholar 

  • Boxer GM, Begent RH, Kelly AM, Southall PJ, Blair SB, Theodorou NA, Dawson PM, Ledermann JA (1992) Factors influencing variability of localisation of antibodies to carcinoembryonic antigen (CEA) in patients with colorectal carcinoma–implications for radioimmunotherapy. Br J Cancer 65:825–831

    Article  PubMed  CAS  Google Scholar 

  • Chester KA, Begent RHJ, Robson L, Keep P, Pedley RB, Boden JA, Boxer G, Green A, Winter G, Cochet O, Hawkins RE (1994) Phage libraries for generation of clinically useful antibodies. Lancet 343:455–456

    Article  PubMed  CAS  Google Scholar 

  • Duff 2006 Expert scientific group on phase one clinical trials. 2006. The Stationery Office, ISBN-13 978 0 11 703722 9

    Google Scholar 

  • Eccles SA, Court WJ, Box GA, Dean CJ, Melton RG, Springer CJ (1994) Regression of established breast carcinoma xenografts with antibody-directed enzyme prodrug therapy against c-erbB2 p185. Cancer Res 54(19):5171–5177

    PubMed  CAS  Google Scholar 

  • Einhorn LH, Williams SD, Chamness A, Brames MJ, Perkins SM, Abonour R (2007) High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumours. N Engl J Med 357(4):340–348

    Article  PubMed  CAS  Google Scholar 

  • Francis RJ, Sharma SK, Springer C, Green AJ, Hope-Stone LD, Sena L, Martin J, Adamson KL, Robbins A, Gumbrell L, O'Malley D, Tsiompanou E, Shahbakhti H, Webley S, Hochhauser D, Hilson AJ, Blakey D, Begent RH (2002) A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours. Br J Cancer 87(6):600–607

    Article  PubMed  CAS  Google Scholar 

  • Haisma HJ, Brakenhoff RH, vd Meulen-Muileman I, Pinedo HM, Boven E (1998) Construction and characterization of a fusion protein of single-chain anti-carcinoma antibody 323/A3 and human beta-glucuronidase. Cancer Immunol Immunother 45(5):266–272

    Article  PubMed  CAS  Google Scholar 

  • Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57–70

    Article  PubMed  CAS  Google Scholar 

  • Harding FA, Liu AD, Stickler M, Razo OJ, Chin R, Faravashi N, Viola W, Graycar T, Yeung VP, Aehle W, Meijer D, Wong S, Rashid MH, Valdes AM, Schellenberger V (2005) B-lactamase with reduced immunogenicity for the targeted delivery of chemotherapeutics using antibody-directed enzyme prodrug therapy. Mol Cancer Ther 4(11):1791–1800

    Article  PubMed  CAS  Google Scholar 

  • Jones PA, Baylin SB (2007) The epigenomics of cancer. Cell 128:683–692

    Article  PubMed  CAS  Google Scholar 

  • Kogelberg H, Tolner B, Sharma SK, Lowdell MW, Qureshi U, Robson M, Hillyer T, Pedley RB, Vervecken W, Contreras R, Begent RH, Chester KA (2007) Clearance mechanism of a mannosylated antibody-enzyme fusion protein used in experimental cancer therapy. Glycobiology 17(1):36–45

    Article  PubMed  CAS  Google Scholar 

  • Mayer A, Tsiompanou E, O'Malley D, Boxer GM, Bhatia J, Flynn AA, Chester KA, Davidson BR, Lewis AA, Winslet MC, Dhillon AP, Hilson AJ, Begent RH (2000) Radioimmunoguided surgery in colorectal cancer using a genetically engineeredanti-CEA single-chain Fv antibody.Clin. Cancer Res 6:1711–1719

    CAS  Google Scholar 

  • Mayer A, Sharma SK, Tolner B, Minton NP, Purdy D, Amlot P, Tharakan G, Begent RH, Chester KA (2004) Modifying an immunogenic epitope on a therapeutic protein: a step towards an improved system for antibody-directed enzyme prodrug therapy (ADEPT). Br J Cancer 90(12):2404–2410

    Google Scholar 

  • Mayer A, Francis RJ, Sharma SK, Tolner B, Springer CJ, Martin J, Boxer GM, Bell J, Green AJ, Hartley JA, Cruickshank C, Wren J, Chester KA, Begent RHJ (2006) A phase I study of single administration of antibody-directed enzyme prodrug therapy with the recombinant anti-carcinoembryonic antigen antibody-enzyme fusion protein mfecp1 and a bis-iodo phenol mustard prodrug. Clin Cancer Res 12:6509–6516

    Article  PubMed  CAS  Google Scholar 

  • Medzihradszky KF, Spencer DI, Sharma SK, Bhatia J, Pedley RB, Read DA, Begent RH, Chester KA (2004) Glycoforms obtained by expression in Pichia pastoris improve cancer targeting potential of a recombinant antibody-enzyme fusion protein. Glycobiology 14(1):27–37 Epub 2003 Sep 26

    Article  PubMed  CAS  Google Scholar 

  • Melo JV, Barnes DJ (2007) Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer 7:441–453

    Article  PubMed  CAS  Google Scholar 

  • Michael NP, Chester KA, Melton RG, Robson L, Nicholas W, Boden JA, Pedley RB, Begent RHJ, Sherwood RF, Minton NP (1996) In vitro and in vivo characterisation of a recombinant carboxypeptidase G2::anti-CEA scFv fusion protein. Immunotechnology 2:47–57

    Article  PubMed  CAS  Google Scholar 

  • Napier MP, Sharma SK, Springer CJ, Bagshawe KD, Green AJ, Martin J, Stribbling SM, Cushen N, O'Malley D, Begent RHJ (2000) Antibody-directed enzyme prodrug therapy: efficacy and mechanism of action in colorectal carcinoma. Clin Cancer Res 6:765–772

    PubMed  CAS  Google Scholar 

  • Pedley RB, Boxer GM, Boden JA, Southall PJ, Begent RH, Bagshawe KD, Humm J, Searle F (1990) Preliminary observations on the microdistribution of labelled antibodies in human colonic adenocarcinoma xenografts: relevance to microdosimetry. Br J Cancer 61:218–220

    Article  PubMed  CAS  Google Scholar 

  • Rubin CP, Heinrich MC, Corless CL (2007) Gastrointestinal stromal tumour. Lancet 369:1731–1741

    Article  PubMed  CAS  Google Scholar 

  • Senter PD (1990) Activation of prodrugs by antibody-enzyme conjugates: a new approach to cancer therapy. FASEB J 4:188–193

    PubMed  CAS  Google Scholar 

  • Senter PD, Springer CJ (2001) Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates. Adv Drug Deliv Rev 53(3):247–264

    Article  PubMed  CAS  Google Scholar 

  • Sharma SK, Pedley RB, Bhatia J, Boxer GM, El-Emir E, Qureshi U, Tolner B, Lowe H, Michael NP, Minton N, Begent RH, Chester KA (2005) Sustained tumour regression of human colorectal cancer xenografts using a multifunctional mannosylated fusion protein in antibody-directed enzyme prodrug therapy. Clin Cancer Res 11:814–825

    PubMed  CAS  Google Scholar 

  • Spencer DI, Robson L, Purdy D, Whitelegg NR, Michael NP, Bhatia J, Sharma SK, Rees AR, Minton NP, Begent RH, Chester KA (2002) A strategy for mapping and neutralizing conformational immunogenic sites on protein therapeutics. Proteomics 2(3):271–279

    Article  PubMed  CAS  Google Scholar 

  • Springer CJ, Dowell R, Burke PJ, Hadley E, Davis DH, Blakey DC, Melton RG, Niculescu-Duvaz I (1995) Optimization of alkylating agent prodrugs derived from phenol and aniline mustards: a new clinical candidate prodrug (ZD2767) for antibody-directed enzyme prodrug therapy (ADEPT). J Med Chem 38(26):5051–5065

    Article  PubMed  CAS  Google Scholar 

  • Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD, Panoskaltsis N (2006) Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 355:1018–1028

    Article  PubMed  CAS  Google Scholar 

  • Tolner B, Smith L, Begent RHJ, Chester KA (2006a) Production of recombinant protein in Pichia pastoris by fermentation. Nat Protoc 1:1006–1021

    Article  PubMed  CAS  Google Scholar 

  • Tolner B, Smith L, Begent RHJ (2006b) Chester KA Expanded-bed adsorption immobilized-metal affinity chromatography. Nat Protocart 1:1213–1222

    Article  CAS  Google Scholar 

  • Webley SD, Francis RJ, Pedley RB, Sharma SK, Begent RH, Hartley JA, Hochhauser D (2001) Measurement of the critical DNA lesions produced by antibody-directed enzyme prodrug therapy (ADEPT) in vitro, in vivo and in clinical material. Br J Cancer 84(12):1671–1676

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The work described was supported by Cancer Research UK, the UCL Experimental Cancer Medicine Centre and the UCL Cancer Institute Research Trust. The author is partly supported by the UCL/UCLH Comprehensive Biomedical Research Centre.

Author information

Authors and Affiliations

  1. Department of Oncology, UCL Cancer Institute, 72 Huntley Street, London, WC1E 6BT, UK

    Richard Begent, Surinder Sharma & Kerry Chester

Authors
  1. Richard Begent
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Surinder Sharma
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kerry Chester
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Richard Begent .

Editor information

Editors and Affiliations

  1. (Biomedical Engineering) Institut für Zellbiologie und Immunologie, Universität Stuttgart, Allmandring 31, 70569, Stuttgart, Germany

    Roland Kontermann

  2. Technische Universität Braunschweig, Institut für Biochemie und Biotechnologie, Spielmannstraße 7, 38106, Braunschweig, Germany

    Stefan Dübel

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer-Verlag

About this protocol

Cite this protocol

Begent, R., Sharma, S., Chester, K. (2010). Antibody-Dependent Enzyme Prodrug Therapy (ADEPT). In: Kontermann, R., Dübel, S. (eds) Antibody Engineering. Springer Protocols Handbooks. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-01144-3_28

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-01144-3_28

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-01143-6

  • Online ISBN: 978-3-642-01144-3

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation